Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib

Naokazu Chiba, Yosuke Ozawa, Kosuke Hikita, Masaaki Okihara, Toru Sano, Koichi Tomita, Kiminori Takano, Shigeyuki Kawachi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

At advanced stages of hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only effective treatment. Surrogate markers that predict the biological and clinical efficacy of sorafenib may help tailor treatment on an individual patient basis. In the present study, the clinical significance of the expression of HOXB9, a transcriptional factor, in HCC was assessed. Increased HOXB9 expression in HCC was found to be positively correlated with the expression of angiogenic factors, increased vascular invasion and was found to be associated with poor overall patient survival. Sorafenib treatment effectively suppressed the expression of angiogenic factors and activation of the Raf/MEK/ERK pathway in HOXB9-expressing HCC cell lines. Consistent with these findings, HCC patients, whose cancer expressed high levels of HOXB9, exhibited increased overall survival upon sorafenib treatment. Collectively, these results suggest that HOXB9 expression in HCC could be a surrogate marker for a beneficial response to sorafenib treatment.

Original languageEnglish
Pages (from-to)2270-2276
Number of pages7
JournalOncology Reports
Volume37
Issue number4
DOIs
Publication statusPublished - 2017 Apr 1
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Survival
Angiogenesis Inducing Agents
Biomarkers
Therapeutics
MAP Kinase Signaling System
Blood Vessels
sorafenib
Cell Line
Neoplasms

Keywords

  • Angiogenesis
  • H epatocellular carcinoma
  • H OXB9
  • Liver cancer
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib. / Chiba, Naokazu; Ozawa, Yosuke; Hikita, Kosuke; Okihara, Masaaki; Sano, Toru; Tomita, Koichi; Takano, Kiminori; Kawachi, Shigeyuki.

In: Oncology Reports, Vol. 37, No. 4, 01.04.2017, p. 2270-2276.

Research output: Contribution to journalArticle

Chiba, N, Ozawa, Y, Hikita, K, Okihara, M, Sano, T, Tomita, K, Takano, K & Kawachi, S 2017, 'Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib', Oncology Reports, vol. 37, no. 4, pp. 2270-2276. https://doi.org/10.3892/or.2017.5474
Chiba, Naokazu ; Ozawa, Yosuke ; Hikita, Kosuke ; Okihara, Masaaki ; Sano, Toru ; Tomita, Koichi ; Takano, Kiminori ; Kawachi, Shigeyuki. / Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib. In: Oncology Reports. 2017 ; Vol. 37, No. 4. pp. 2270-2276.
@article{27b0647d78664d18a50e77c8d1a53d10,
title = "Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib",
abstract = "At advanced stages of hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only effective treatment. Surrogate markers that predict the biological and clinical efficacy of sorafenib may help tailor treatment on an individual patient basis. In the present study, the clinical significance of the expression of HOXB9, a transcriptional factor, in HCC was assessed. Increased HOXB9 expression in HCC was found to be positively correlated with the expression of angiogenic factors, increased vascular invasion and was found to be associated with poor overall patient survival. Sorafenib treatment effectively suppressed the expression of angiogenic factors and activation of the Raf/MEK/ERK pathway in HOXB9-expressing HCC cell lines. Consistent with these findings, HCC patients, whose cancer expressed high levels of HOXB9, exhibited increased overall survival upon sorafenib treatment. Collectively, these results suggest that HOXB9 expression in HCC could be a surrogate marker for a beneficial response to sorafenib treatment.",
keywords = "Angiogenesis, H epatocellular carcinoma, H OXB9, Liver cancer, Sorafenib",
author = "Naokazu Chiba and Yosuke Ozawa and Kosuke Hikita and Masaaki Okihara and Toru Sano and Koichi Tomita and Kiminori Takano and Shigeyuki Kawachi",
year = "2017",
month = "4",
day = "1",
doi = "10.3892/or.2017.5474",
language = "English",
volume = "37",
pages = "2270--2276",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib

AU - Chiba, Naokazu

AU - Ozawa, Yosuke

AU - Hikita, Kosuke

AU - Okihara, Masaaki

AU - Sano, Toru

AU - Tomita, Koichi

AU - Takano, Kiminori

AU - Kawachi, Shigeyuki

PY - 2017/4/1

Y1 - 2017/4/1

N2 - At advanced stages of hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only effective treatment. Surrogate markers that predict the biological and clinical efficacy of sorafenib may help tailor treatment on an individual patient basis. In the present study, the clinical significance of the expression of HOXB9, a transcriptional factor, in HCC was assessed. Increased HOXB9 expression in HCC was found to be positively correlated with the expression of angiogenic factors, increased vascular invasion and was found to be associated with poor overall patient survival. Sorafenib treatment effectively suppressed the expression of angiogenic factors and activation of the Raf/MEK/ERK pathway in HOXB9-expressing HCC cell lines. Consistent with these findings, HCC patients, whose cancer expressed high levels of HOXB9, exhibited increased overall survival upon sorafenib treatment. Collectively, these results suggest that HOXB9 expression in HCC could be a surrogate marker for a beneficial response to sorafenib treatment.

AB - At advanced stages of hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only effective treatment. Surrogate markers that predict the biological and clinical efficacy of sorafenib may help tailor treatment on an individual patient basis. In the present study, the clinical significance of the expression of HOXB9, a transcriptional factor, in HCC was assessed. Increased HOXB9 expression in HCC was found to be positively correlated with the expression of angiogenic factors, increased vascular invasion and was found to be associated with poor overall patient survival. Sorafenib treatment effectively suppressed the expression of angiogenic factors and activation of the Raf/MEK/ERK pathway in HOXB9-expressing HCC cell lines. Consistent with these findings, HCC patients, whose cancer expressed high levels of HOXB9, exhibited increased overall survival upon sorafenib treatment. Collectively, these results suggest that HOXB9 expression in HCC could be a surrogate marker for a beneficial response to sorafenib treatment.

KW - Angiogenesis

KW - H epatocellular carcinoma

KW - H OXB9

KW - Liver cancer

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85016404576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016404576&partnerID=8YFLogxK

U2 - 10.3892/or.2017.5474

DO - 10.3892/or.2017.5474

M3 - Article

C2 - 28260092

AN - SCOPUS:85016404576

VL - 37

SP - 2270

EP - 2276

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -